- Home
- MCRB vs ICAD Comparison
MCRB vs ICAD Comparison
Compare MCRB & ICAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- ICAD
- Stock Information
- Founded
- MCRB 2010
- ICAD 1984
- Country
- MCRB United States
- ICAD United States
- Employees
- MCRB N/A
- ICAD N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- ICAD Medical/Dental Instruments
- Sector
- MCRB Health Care
- ICAD Health Care
- Exchange
- MCRB Nasdaq
- ICAD Nasdaq
- Market Cap
- MCRB 81.2M
- ICAD 93.9M
- IPO Year
- MCRB 2015
- ICAD 1986
- Fundamental
- Price
- MCRB $7.06
- ICAD $3.60
- Analyst Decision
- MCRB Hold
- ICAD Hold
- Analyst Count
- MCRB 5
- ICAD 1
- Target Price
- MCRB $73.67
- ICAD N/A
- AVG Volume (30 Days)
- MCRB 146.8K
- ICAD 1.8M
- Earning Date
- MCRB 05-07-2025
- ICAD 05-19-2025
- Dividend Yield
- MCRB N/A
- ICAD N/A
- EPS Growth
- MCRB N/A
- ICAD N/A
- EPS
- MCRB 0.03
- ICAD N/A
- Revenue
- MCRB N/A
- ICAD $19,608,000.00
- Revenue This Year
- MCRB N/A
- ICAD $2.58
- Revenue Next Year
- MCRB N/A
- ICAD $14.78
- P/E Ratio
- MCRB $213.09
- ICAD N/A
- Revenue Growth
- MCRB N/A
- ICAD 13.22
- 52 Week Low
- MCRB $7.18
- ICAD $1.18
- 52 Week High
- MCRB $30.60
- ICAD $3.78
- Technical
- Relative Strength Index (RSI)
- MCRB 33.07
- ICAD 72.92
- Support Level
- MCRB $8.92
- ICAD $3.42
- Resistance Level
- MCRB $9.97
- ICAD $3.58
- Average True Range (ATR)
- MCRB 1.08
- ICAD 0.13
- MACD
- MCRB -0.06
- ICAD 0.03
- Stochastic Oscillator
- MCRB 10.61
- ICAD 78.08
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About ICAD iCAD Inc.
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment includes image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.